Century Therapeutics Reports Preclinical Success for Immune-Evasive Beta Islet Therapy in Type 1 Diabetes

Reuters11-13

Century <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Preclinical Success for Immune-Evasive Beta Islet Therapy in Type 1 Diabetes

Century Therapeutics Inc. has announced compelling preclinical research results for its new Type 1 diabetes program, CNTY-813. The therapy uses iPSC-derived beta islets engineered with the company's Allo-Evasion™ 5.0 technology to overcome immune rejection and provide durable glucose control without the need for chronic immunosuppression. According to Century, preclinical data show rapid and sustained normalization of glucose levels in diabetic mouse models, significant glucose-stimulated insulin secretion, and resistance to immune cell-mediated rejection. The company also reported success in producing these beta islets at scale using a suspension bioreactor process. IND-enabling studies are on track to begin by the end of 2025, with an IND submission planned as early as 2026. The announcement does not specify if or when these results have been or will be presented at a scientific meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574692-en) on November 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583456254?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583456254","market":"fut","top_or_hot":-1,"title":"Century Therapeutics Reports Preclinical Success for Immune-Evasive Beta Islet Therapy in Type 1 Diabetes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Century <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Preclinical Success for Immune-Evasive Beta Islet Therapy in Type 1 Diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Century Therapeutics Inc. has announced compelling preclinical research results for its new Type 1 diabetes program, CNTY-813. The therapy uses iPSC-derived beta islets engineered with the company's Allo-Evasion™ 5.0 technology to overcome immune rejection and provide durable glucose control without the need for chronic immunosuppression. According to Century, preclinical data show rapid and sustained normalization of glucose levels in diabetic mouse models, significant glucose-stimulated insulin secretion, and resistance to immune cell-mediated rejection. The company also reported success in producing these beta islets at scale using a suspension bioreactor process. IND-enabling studies are on track to begin by the end of 2025, with an IND submission planned as early as 2026. The announcement does not specify if or when these results have been or will be presented at a scientific meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574692-en) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Century Therapeutics Reports Preclinical Success for Immune-Evasive Beta Islet Therapy in Type 1 Diabetes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCentury Therapeutics Reports Preclinical Success for Immune-Evasive Beta Islet Therapy in Type 1 Diabetes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Century <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Preclinical Success for Immune-Evasive Beta Islet Therapy in Type 1 Diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Century Therapeutics Inc. has announced compelling preclinical research results for its new Type 1 diabetes program, CNTY-813. The therapy uses iPSC-derived beta islets engineered with the company's Allo-Evasion™ 5.0 technology to overcome immune rejection and provide durable glucose control without the need for chronic immunosuppression. According to Century, preclinical data show rapid and sustained normalization of glucose levels in diabetic mouse models, significant glucose-stimulated insulin secretion, and resistance to immune cell-mediated rejection. The company also reported success in producing these beta islets at scale using a suspension bioreactor process. IND-enabling studies are on track to begin by the end of 2025, with an IND submission planned as early as 2026. The announcement does not specify if or when these results have been or will be presented at a scientific meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574692-en) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL2CfhmS:1","article_id":"2583456254","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583456254","pubTimestamp":1763035238,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Century Therapeutics Inc. has announced compelling preclinical research results for its new Type 1 diabetes program, CNTY-813. The therapy uses iPSC-derived beta islets engineered with the company's Allo-Evasion 5.0 technology to overcome immune rejection and provide durable glucose control without the need for chronic immunosuppression. According to Century, preclinical data show rapid and sustained normalization of glucose levels in diabetic mouse models, significant glucose-stimulated insulin secretion, and resistance to immune cell-mediated rejection. The company also reported success in producing these beta islets at scale using a suspension bioreactor process. IND-enabling studies are on track to begin by the end of 2025, with an IND submission planned as early as 2026. The announcement does not specify if or when these results have been or will be presented at a scientific meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelli","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4539":"次新股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","IPSC":"Century Therapeutics, Inc.","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4505":"高瓴资本持仓","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","BK4139":"生物科技","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Century Therapeutics报告免疫逃逸β胰岛疗法在1型糖尿病中取得临床前成功","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"IPSC":0.9},"content_text":"Century Therapeutics Reports Preclinical Success for Immune-Evasive Beta Islet Therapy in Type 1 Diabetes\n    \n\n        Century Therapeutics Inc. has announced compelling preclinical research results for its new Type 1 diabetes program, CNTY-813. The therapy uses iPSC-derived beta islets engineered with the company's Allo-Evasion™ 5.0 technology to overcome immune rejection and provide durable glucose control without the need for chronic immunosuppression. According to Century, preclinical data show rapid and sustained normalization of glucose levels in diabetic mouse models, significant glucose-stimulated insulin secretion, and resistance to immune cell-mediated rejection. The company also reported success in producing these beta islets at scale using a suspension bioreactor process. IND-enabling studies are on track to begin by the end of 2025, with an IND submission planned as early as 2026. The announcement does not specify if or when these results have been or will be presented at a scientific meeting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574692-en) on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583456254","isCrawlerRequest":true}